Mizuho Cuts Revance Therapeutics (NASDAQ:RVNC) Price Target to $3.10

Revance Therapeutics (NASDAQ:RVNC) had its price target cut by Mizuho from $6.66 to $3.10 in a research note issued to investors on Tuesday,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

A number of other research firms also recently weighed in on RVNC. Guggenheim reiterated a “neutral” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Piper Sandler lowered shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. StockNews.com initiated coverage on shares of Revance Therapeutics in a research report on Wednesday, December 4th. They issued a “hold” rating for the company. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Finally, William Blair restated a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Revance Therapeutics currently has an average rating of “Hold” and a consensus target price of $8.96.

Revance Therapeutics Stock Up 1.6 %

Shares of Revance Therapeutics stock opened at $3.09 on Tuesday. The stock has a market capitalization of $324.15 million, a price-to-earnings ratio of -1.60 and a beta of 0.81. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $9.74. The company has a 50-day simple moving average of $4.60 and a two-hundred day simple moving average of $4.46.

Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. On average, sell-side analysts anticipate that Revance Therapeutics will post -1.54 earnings per share for the current fiscal year.

Institutional Trading of Revance Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RVNC. Certuity LLC bought a new position in shares of Revance Therapeutics in the 2nd quarter valued at $26,000. Vanguard Personalized Indexing Management LLC bought a new position in Revance Therapeutics in the second quarter valued at about $33,000. Hsbc Holdings PLC acquired a new stake in shares of Revance Therapeutics during the second quarter valued at about $38,000. Nisa Investment Advisors LLC grew its holdings in shares of Revance Therapeutics by 2,167.5% during the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 18,077 shares during the last quarter. Finally, FORA Capital LLC acquired a new position in shares of Revance Therapeutics in the third quarter valued at approximately $54,000. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.